Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
山东绿叶制药有限公司 Lvye
{{company.company_channel.channel_name}}
Media Room
Latest
Photos
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Follow :
X
Company Profile
Media Room
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.title}}
loading
The End
Network Errors Please Retry
{{selectname}}
{{showName}}
{{selectall}}
{{option}}
Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for Treating Schizophrenia and Schizoaffective Disorder
2024-07-28 21:48
NDA for Luye Pharma's Rivastigmine Twice Weekly Transdermal Patch Filed in Japan for Treating Alzheimer's Dementia
2024-06-06 17:33
Luye Pharma's Innovative Drug Zepzelca® (Lurbinectedin) Launched in Hong Kong and Macao
2024-03-07 10:11
Luye Pharma Grants Myung In Pharm Exclusive Rights to Commercialize Rivastigmine Twice Weekly Transdermal Patch in South Korea
2024-02-05 18:53
Boan Biotech's Biologics License Application for Boyounuo® (Bevacizumab Injection) Accepted in Brazil
2023-04-11 20:19
Luye Pharma and Duopharma Reach Strategic Partnership to Expand Accessibility of Cholesterol Management Products in Malaysia
2023-04-05 10:44
Boan Biotech Announces 2022 Financial Results
2023-03-27 23:15
BLA Accepted in China for Boan Biotech's Denosumab Injection (BA1102) for the Oncology Indications
2023-03-21 13:46
Patient Enrollment Completed for the Phase 3 Trial of Boan Biotech's Aflibercept Intravitreous Injection in China
2023-03-13 20:36
Boan Biotech's Investigational Long-acting Anti-IL-4Rα Antibody BA2101 Administered for First Patient in Phase I Clinical Trial
2023-02-16 08:15
Boan Biotech's Investigational Anti-CD25 Antibody BA1106 Administered for First Patient in Phase I Clinical Trial
2023-02-13 08:39
Luye Pharma's Innovative Anti-Cancer Therapy Lurbinectedin to Benefit "Named Patients" in Hong Kong
2023-01-09 18:57
Luye Pharma and DCH Auriga Establish an Exclusive Distribution Partnership and Jointly Launch the "We Care About Mental Health" Initiative
2022-12-13 12:14
Luye Pharma Enters Local Seroquel® Distribution and Marketing Partnership with ICI Pakistan Limited
2022-09-27 07:59
Luye Pharma Grants Laboratorio LIBRA Exclusive Marketing Rights for Seroquel and Seroquel XR in Chile
2022-02-09 11:57
Luye Pharma Releases Top-Line Results from a Phase II Clinical Trial of Its New Antidepressant Ansofaxine Hydrochloride Extended-Release Tablets
2021-12-23 16:23
Luye Pharma Grants Zambon Exclusive Commercialization Rights to Its Innovative Alzheimer's Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Switzerland
2021-11-10 23:38
Boan Biotech to Present the Pre-clinical Data of Its Proprietary CD3+ T-cell Engager Platform and CEA/CD3 Bispecific Antibody at World Bispecific Summit
2021-09-26 10:12
Luye Pharma Becomes the Marketing Authorization Holder for Seroquel and Seroquel XR in Saudi Arabia
2021-09-17 22:16
Luye Pharma Enters Distribution Agreement with Zuellig Pharma for Seroquel and Seroquel XR in Malaysia and Brunei, Strengthening Business Presence in Asia Pacific and Improving Access to Evidence-Based Medical Treatments for Mental Health
2021-08-02 10:25
1
2
3